Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin

Joon Tae Park, Xu Chen, Claes G. Tropè, Ben Davidson, Ie Ming Shih, Tian Li Wang

Research output: Contribution to journalArticlepeer-review

117 Scopus citations


Amplification of the Notch3 locus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant type of ovarian cancer. We have previously demonstrated that ovarian cancer cells, which amplified and overexpressed Notch3, were dependent on Notch3 signaling for cellular survival and growth. In this study, we provide new evidence that Notch3 expression is associated with recurrent postchemotherapy HGSCs. Moreover, patients with recurrent HGSCs in effusion with high Notch3 expression had a significantly worse clinical outcome, including reduced overall survival and shortened progression-free survival than did patients with low Notch3 expressing HGSC. Ectopic expression of the Notch3 intracellular domain led to an increase in IC50 for carbo-platin in an ovarian surface epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable levels of Notch3. Interestingly, expression of the Notch3 intracellular domain increased expression of several genes associated with embryonic stem cells including Nanog, Oct4, Klf4, Rex1, Rif1, Sall4, and NAC1 as well as an ATP-dependent transporter gene, ABCB1. Knockdown of Notch3 resulted in sensitization to carboplatin in OVCAR3 that expresses abundant Notch3. Taken together, the above findings suggest that Notch3 pathway activation reprograms tumor cells to assume an array of embryonic stem cell markers and participates in development of chemoresistance in HGSC.

Original languageEnglish (US)
Pages (from-to)1087-1094
Number of pages8
JournalAmerican Journal of Pathology
Issue number3
StatePublished - Sep 2010

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin'. Together they form a unique fingerprint.

Cite this